Journal
SCHIZOPHRENIA BULLETIN
Volume 40, Issue -, Pages S165-S194Publisher
OXFORD UNIV PRESS
DOI: 10.1093/schbul/sbu006
Keywords
schizophrenia; health policy; quality of life; antipsychotics; psychotherapy; recovery
Categories
Funding
- F. Hoffmann-La Roche
- Janssen
- Otsuka
- Pfizer
- Reckitt Benckiser
- Abbott
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Caja Navarra
- Centro de Investigacion Biomdica en Red de Salud Mental
- Fundacion Alicia Koplowitz
- Instituto de Salud Carlos III
- Janssen-Cilag
- Lundbeck
- Merck
- Ministerio de Ciencia e Innovacion
- Ministerio de Economia y Competitividad
- Ministerio de Sanidad
- Mutua Madrilena
- Oxford PharmaGenesis Ltd
- Roche
- Schering-Plough
- Servier
- Shire
- Takeda
- Department of Health for England
- Lilly
Ask authors/readers for more resources
Care and outcomes for people with schizophrenia have improved in recent years, but further progress is needed to help more individuals achieve an independent and fulfilled life. This report sets out the current need, informs policy makers and all relevant stakeholders who influence care quality, and supports their commitment to creating a better future. The authors recommend the following policy actions, based on research evidence, stakeholder consultation, and examples of best practice worldwide. (1) Provide an evidence-based, integrated care package for people with schizophrenia that addresses their mental and physical health needs. (2) Provide support for people with schizophrenia to enter and to remain in their community, and develop mechanisms to help guide them through the complex benefit and employment systems. (3) Provide concrete support, information, and educational programs to families and carers on how to enhance care for an individual living with schizophrenia in a manner that entails minimal disruption to their lives. (4) All stakeholders, including organizations that support people living with schizophrenia, should be consulted to regularly revise, update, and improve policy on the management of schizophrenia. (5) Provide support, which is proportionate to the impact of the disease, for research and development of new treatments. (6) Establish adequately funded, ongoing, and regular awareness-raising campaigns that form an integral part of routine plans of action. Implementation of the above recommendations will require engagement by every stakeholder, but with commitment from all, change can be achieved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available